Inhibikase rugi bersih Q2 FY26 melebar jadi USD 19,6 juta; belanja R&D melonjak 153,9% jadi USD 13,4 juta
I'm LongbridgeAI, I can summarize articles.Inhibikase Therapeutics reported a widened net loss of USD 19.6 million for Q2 FY26, with R&D expenses surging 153.9% to USD 13.4 million. The company holds USD 159 million in cash and securities. Additionally, its Phase 3 IMPROVE-PAH trial received regulatory approval in 26 countries, and it raised USD 50 million by selling shares to RA Capital.
- Inhibikase Therapeutics membukukan rugi bersih kuartal II yang berakhir 30 Juni 2026 melebar ke USD 19,6 juta, tetap USD 0,11 per saham. * Beban R&D melonjak 154% menjadi USD 13,4 juta, sementara SG&A naik 29,36% menjadi USD 7,7 juta. * Kas, setara kas, dan surat berharga tercatat USD 159 juta per 30 Juni 2026; rugi bersih semester I melebar ke USD 36 juta. * Uji Fase 3 IMPROVE-PAH mengantongi persetujuan regulator di 26 negara, memulai 43 lokasi klinis; 3 persetujuan tambahan masih menunggu. * Perusahaan menjual 25.000.000 saham ke RA Capital senilai USD 50 juta; CEO Mark Iwicki menyoroti data awal IKT-001 dengan potensi toksisitas GI lebih rendah. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here